Taltz

Taltz

ixekizumab

Manufacturer:

Eli Lilly

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ixekizumab
Indications/Uses
Moderate to severe plaque psoriasis in adults, in childn ≥6 yr & adolescents who are candidates for systemic therapy. Alone or in combination w/ methotrexate for active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 disease-modifying anti-rheumatic drug (DMARD) therapies. Adults w/ active ankylosing spondylitis who have responded inadequately to conventional therapy. Adults w/ active non-radiographic axial spondyloarthritis w/ objective signs of inflammation who have responded inadequately to NSAIDs.
Dosage/Direction for Use
SC Plaque psoriasis Adult 160 mg (as two 80 mg inj) at wk 0, followed by 80 mg at wk 2, 4, 6, 8, 10 & 12. Maintenance dose: 80 mg every 4 wk. Paed 6 to <18 yr weighing >50 kg Recommended starting dose (wk 0): 160 mg (as two 80 mg inj) then 80 mg every 4 wk thereafter; 25-50 kg Recommended starting dose (wk 0): 80 mg then 40 mg every 4 wk thereafter; <25 kg Recommended starting dose (wk 0): 40 mg then 20 mg every 4 wk thereafter. Psoriatic arthritis, axial spondyloarthritis (radiographic & non-radiographic) 160 mg (as two 80 mg inj) at wk 0, followed by 80 mg every 4 wk thereafter. Psoriatic arthritis w/ concomitant moderate to severe plaque psoriasis Recommended dose: 160 mg (as two 80 mg inj) at wk 0, followed by 80 mg at wk 2, 4, 6, 8, 10 & 12. Maintenance dose: 80 mg every 4 wk.
Contraindications
Serious hypersensitivity. Active infections (eg, active TB).
Special Precautions
Discontinue immediately & initiate appropriate therapy if serious hypersensitivity reaction occurs. Increased rate of infections eg, upper resp tract infection, oral candidiasis, conjunctivitis & tinea infections. Patients w/ chronic infection or history of recurrent infection. Carefully monitor & discontinue treatment if patient is unresponsive to standard therapy or for serious infection. Should not be given to patients w/ active TB. Consider anti-TB therapy prior to initiation in patients w/ latent TB. Not recommended in patients w/ inflammatory bowel disease. Concomitant use w/ live vaccines. Women of childbearing potential should use effective contraception method during treatment & for at least 10 wk after treatment. Avoid use in pregnancy. Lactation. Childn & adolescents 2 to <18 yr in treatment of psoriatic arthritis. Elderly ≥75 yr.
Adverse Reactions
Upper resp tract infection; inj site reactions. Tinea infection, herpes simplex (mucocutaneous); oropharyngeal pain; nausea.
MIMS Class
Immunosuppressants
ATC Classification
L04AC13 - ixekizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Taltz soln for inj 80 mg/mL
Packing/Price
1 mL x 1's;1's
/thailand/image/info/taltz soln for inj 80 mg-ml/80 mg-ml?id=56c44f16-dbcd-47fa-a618-ab980105e36a
/thailand/image/info/taltz soln for inj 80 mg-ml/80 mg-ml?id=b39385c8-e560-4461-932f-ab980105e36a
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in